Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018 · Journal of Hematology & Oncology · 790 citations
https://doi.org/10.1186/s13045-018-0582-8
Y
Yanyan Lou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
281
Papers
8.4K
Citations
42
h-index
71
i10-index
Yanyan Lou is an academic researcher from University of Nottingham Ningbo China. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Lung Cancer Research Studies. The author has an h-index of 42, co-authored 239 publications.
ORCID: 0000-0001-6207-9461Papers by this author
worksEmerging therapeutic agents for advanced non-small cell lung cancer
2020 · Journal of Hematology & Oncology · 365 citations
https://doi.org/10.1186/s13045-020-00881-7
The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy
2018 · Cell Systems · 340 citations
https://doi.org/10.1016/j.cels.2018.01.013
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
2017 · PharmacoEconomics · 149 citations
https://doi.org/10.1007/s40273-017-0527-z
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
2021 · JNCI Journal of the National Cancer Institute · 103 citations
https://doi.org/10.1093/jnci/djab035
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
2022 · Journal for ImmunoTherapy of Cancer · 102 citations
https://doi.org/10.1136/jitc-2021-003779
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat